April 24, 2024
A Purdue University professor’s invention that measures concrete strength for highway traffic won gold at the Edison Awards in its Best New Products competition on April 18 in the Critical Human Infrastructure category, according to the award’s website.
April 23, 2024
Researchers at Purdue University have made groundbreaking strides in developing a novel treatment for glioblastoma brain tumors, a condition deemed incurable with conventional therapies.
April 23, 2024
A new type of immunotherapy drug appears to be more effective than other approaches at stimulating the immune response, the results of a study published April 19 in Nature Biomedical Engineering show.
Combining the 'best of two worlds' to boost immunotherapy response in mice with breast cancer
April 23, 2024
Hot flashes are one of the most commonly discussed side effects of menopause, but the decline of ovarian hormones and its effect on the gut microbiome can also increase the risk of a variety of metabolic diseases, including obesity and cardiometabolic syndrome, according to a recent publication by Tzu-Wen Cross, assistant professor in Purdue University’s Department Nutrition Science.
PURDUE NUTRITION SCIENCE RESEARCHER UNCOVERS CONNECTION BETWEEN HORMONES, GUT MICROBIOME AND METABOLIC DYSFUNCTION COMMONLY SEEN IN POSTMENOPAUSAL WOMEN
April 23, 2024
As the world emerges from the COVID-19 pandemic, there is an urgent need to understand patient factors that may be used to predict the occurrence of severe cases and patient mortality.
Identification of predictive patient characteristics for assessing the probability of COVID-19 in-hospital mortality
April 22, 2024
Purdue University researchers are developing and validating a patent-pending treatment for incurable glioblastoma brain tumors. Glioblastomas are almost always lethal with a median survival time of 14 months. Traditional methods used against other cancers, like chemotherapy and immunotherapy, are often ineffective on glioblastoma.
Genetically engineering a treatment for incurable brain tumors
April 22, 2024
Scientists are developing and validating a patent-pending novel immunotherapy to be used against glioblastoma brain tumors. Glioblastomas are almost always lethal with a median survival time of 14 months. Traditional methods used against other cancers, like chemotherapy and immunotherapy, are often ineffective on glioblastoma.
Genetically engineering a treatment for incurable brain tumors
April 22, 2024
Researchers at The University of Texas MD Anderson Cancer Center have unveiled a groundbreaking method in immunotherapy drug development, utilizing engineered peptides that stimulate the body’s immune system to fight cancer more effectively. Published in Nature Biomedical Engineering, their study presents a promising leap forward in treating advanced breast cancer, showcasing enhanced tumor suppression and extended survival rates.
Breakthrough in Cancer Treatment: Novel Engineered Peptides Enhance Immunotherapy Efficacy
April 22, 2024
In a significant milestone for the Purdue Institute for Cancer Research (PICR), faculty, students and staff gathered at the Hansen Life Sciences Research Building on April 17 to honor seven awardees for their outstanding contributions to cancer research. PICR Director Andrew Mesecar delivered remarks emphasizing the importance of establishing the awards ceremony as a tradition and spoke about the distinct contributions each recipient had made to further the institute’s goal of conquering cancer.
First annual PICR Awards ceremony recognizes excellence in cancer research
April 21, 2024
In a new study published in Nature Biomedical Engineering, researchers at The University of Texas MD Anderson Cancer Center have developed a new method for creating immunotherapy drugs using engineered peptides. The study showed that the method improved tumor control and prolonged survival in preclinical models of locally advanced and metastatic breast cancer, both as a monotherapy and in combination with immune checkpoint inhibitors.
New study paves the way for advancements in immunotherapy drug development
